Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase IIb, Open, Multinational, Multi-center, Randomised, Comparative, Parallel Study to Assess the Safety and Antiviral Activity of LB80380 Compared to Entecavir 0.5 mg in Chronic Hepatitis B Patients for 48 Weeks With a Planned Analysis of Efficacy and Safety at Week 24 of the Treatment for Selecting Optimal Dose

NCT01026610 is registered in ClinicalTrials.gov with LG Life Sciences as lead sponsor.

NCT NCT01026610
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01026610 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase IIb, Open, Multinational, Multi-center, Randomised, Comparative, Parallel Study to Assess the Safety and Antiviral Activity of LB80380 Compared to Entecavir 0.5 mg in Chronic Hepatitis B Patients for 48 Weeks With a Planned Analysis of Efficacy and Safety at Week 24 of the Treatment for Selecting Optimal Dose
Lead sponsor
LG Life Sciences
Phase
Phase 2
Overall status
Completed
Start date
August 31, 2009
Completion date
May 31, 2011
Enrollment
115 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

chronic hepatitis b